Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q6960846> ?p ?o }
Showing triples 1 to 40 of
40
with 100 triples per page.
- Q6960846 abstract "Naldemedine (INN, USAN; S-297,995) is a peripherally-selective μ-opioid receptor antagonist under development by Shionogi for the treatment of opioid-induced adverse effects including constipation, nausea, and vomiting. Clinical studies have thus far found it to possess statistically significant effectiveness for these indications and to be generally well-tolerated with predominantly mild to moderate gastrointestinal side effects. No effects indicative of central opioid withdrawal or impact on the analgesic or mydriatic effects of co-administered opioids have been observed. As of July 2014, naldemedine is in phase III clinical trials in the United States and Japan.".
- Q6960846 atcPrefix "None".
- Q6960846 casNumber "916072-89-4".
- Q6960846 casSupplemental "(tosylate)".
- Q6960846 iupacName "(17-(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,6,14-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide)".
- Q6960846 pubchem "135626906".
- Q6960846 thumbnail Naldemedine.svg?width=300.
- Q6960846 wikiPageWikiLink Q127076.
- Q6960846 wikiPageWikiLink Q14911924.
- Q6960846 wikiPageWikiLink Q178436.
- Q6960846 wikiPageWikiLink Q178648.
- Q6960846 wikiPageWikiLink Q186889.
- Q6960846 wikiPageWikiLink Q2047938.
- Q6960846 wikiPageWikiLink Q2585693.
- Q6960846 wikiPageWikiLink Q285166.
- Q6960846 wikiPageWikiLink Q30612.
- Q6960846 wikiPageWikiLink Q3269441.
- Q6960846 wikiPageWikiLink Q3482319.
- Q6960846 wikiPageWikiLink Q410943.
- Q6960846 wikiPageWikiLink Q425265.
- Q6960846 wikiPageWikiLink Q427523.
- Q6960846 wikiPageWikiLink Q4914025.
- Q6960846 wikiPageWikiLink Q4926095.
- Q6960846 wikiPageWikiLink Q539566.
- Q6960846 wikiPageWikiLink Q6060674.
- Q6960846 wikiPageWikiLink Q6431240.
- Q6960846 wikiPageWikiLink Q7814214.
- Q6960846 wikiPageWikiLink Q824258.
- Q6960846 atcPrefix "None".
- Q6960846 casNumber "916072".
- Q6960846 iupacName "(17--6,7-didehydro-4,5α-epoxy-3,6,14-trihydroxy-N-[2-propan-2-yl]morphinan-7-carboxamide)".
- Q6960846 pubchem "135626906".
- Q6960846 type ChemicalSubstance.
- Q6960846 type Drug.
- Q6960846 type ChemicalObject.
- Q6960846 type Thing.
- Q6960846 type Q8386.
- Q6960846 comment "Naldemedine (INN, USAN; S-297,995) is a peripherally-selective μ-opioid receptor antagonist under development by Shionogi for the treatment of opioid-induced adverse effects including constipation, nausea, and vomiting. Clinical studies have thus far found it to possess statistically significant effectiveness for these indications and to be generally well-tolerated with predominantly mild to moderate gastrointestinal side effects.".
- Q6960846 label "Naldemedine".
- Q6960846 depiction Naldemedine.svg.